Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Lantern Pharma Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT06132503
- Locations
- ๐บ๐ธ
Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
๐บ๐ธSTART Mountain Region, West Valley City, Utah, United States
Study of LP-184 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Lantern Pharma Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05933265
- Locations
- ๐บ๐ธ
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
๐บ๐ธUT Health Science Center San Antonio, San Antonio, Texas, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Study of LP-300 with Carboplatin and Pemetrexed in Never Smokers with Advanced Lung Adenocarcinoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-07-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Lantern Pharma Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05456256
- Locations
- ๐บ๐ธ
Los Angeles Cancer Network, Fountain Valley, California, United States
๐ฏ๐ตHokkaido Cancer Center, Sapporo-Shi, Hokkaido, Japan
๐ฏ๐ตKanagawa Cancer Center Hospital, Yokohama-Shi, Kanagawa, Japan
ยฉ Copyright 2024. All Rights Reserved by MedPath